Paper Review Records
All Paper Review Records
30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
26
days
CAR immunotherapy for cancer: from ex vivo manufacturing to in vivo immune cell engineering
Authors
Ziqiang Liu; Dezheng Kong; Pengwu Liang; Zhengze Li; Tingting Tan; Xin Dong; Ruizhen Li; Lifeng Li; Yi Zhang; Guozhu XieShow moreShow less
Affiliations
1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China; 2. Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China; 3. Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; 4. The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 5. National Engineering Laboratory for Internet Medical Systems and Applications, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China; 6. Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaShow moreShow less
282
days
RBP1-driven retinol metabolism in tumor-associated lymphatic endothelial cells orchestrates triple-negative breast cancer progression and lymphatic metastasis
Authors
Nieves Montenegro-Navarro; Estefanía Díaz del Cerro; Carmen Jordán-Pérez; Enrique de Álava; Melissa García-CaballeroShow moreShow less
Affiliations
1. Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga, Málaga, Spain; 2. Biomedical Research Institute of Málaga and Nanotechnology Platform (IBIMA Plataforma BIONAND), Málaga, Spain; 3. Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Molecular Pathology of Sarcomas, Seville, Spain; 4. Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, SpainShow moreShow less
83
days
Distinct asciminib sensitivity profiles between BCR::ABL1 p190 and p210 isoforms
Authors
Elias Lagonik; Luke J. Quinlan; Elyse C. Page; Daniel P. McDougal; Laura N. Eadie; John B. Bruning; David T. Yeung; Timothy P. Hughes; Deborah L. WhiteShow moreShow less
Affiliations
1. Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia; 2. Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, Australia; 3. Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia; 4. Centre for Targeted Protein Degradation, University of Dundee, Dundee, Scotland; 5. Institute for Photonics and Advanced Sensing, School of Biological Sciences, The University of Adelaide, Adelaide, Australia; 6. Haematology Department, Royal Adelaide Hospital, Adelaide, Australia; 7. Australasian Leukaemia Lymphoma Group, Richmond, Australia; 8. Australian and New Zealand Children’s Haematology-Oncology Group, Clayton, AustraliaShow moreShow less
105
days
A non-IMiD multi-target degrader reactivates fetal hemoglobin
Authors
Jun Liu; Ziyang Shen; Shin-Young Park; Yanhua Dong; Na Yu; Jing Zeng; Hannah Lee; Braden Pate; Sophia Adamia; Kim Vanuytsel; Junyan Zhang; Shang-Chuen Wu; Adelaide Herman; Shiva Moein; Wenhui Li; Miao Liu; Chong Gao; Xi Tian; Zhaoji Liu; Junsu Kwon; Kunhua Qin; Christoph Budjan; Claire Shao; Jiajia Li; Ernie Lee; Sanjana Arji; Bee-hui Liu; Sean Stowell; John P. Manis; David Justus; Gerd A. Blobel; Hongbo R. Luo; Roger Belizaire; Yi Zheng; Sahand Hormoz; Mahmoud A. Bassal; Sarah Nikiforow; Jose A. Cancelas; Daniel E. Bauer; Daniel G. Tenen; Li ChaiShow moreShow less
Affiliations
1. Department of Pathology, Brigham and Women’s Hospital, Boston, USA; 2. Department of Pathology, Harvard Medical School, Boston, USA; 3. Division of Hematology/Oncology, Boston Children’s Hospital, Boston, USA; 4. Center for Regenerative Medicine (CReM), Boston University and Boston Medical Center, Boston, USA; 5. Beth Israel Deaconess Medical Center, Boston, USA; 6. Institute of Medical and Public Health Research, Ilia State University, Tbilisi, Georgia; 7. Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, USA; 8. Department of Systems Biology, Harvard Medical School, Boston, USA; 9. Department of Data Science, Dana-Farber Cancer Institute, Boston, USA; 10. Cancer Science Institute of Singapore, Singapore, Singapore; 11. Department of Laboratory Medicine, Boston Children’s Hospital, Boston, USA; 12. Department of Pathology, Dana-Farber Cancer Institute, Boston, USA; 13. Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 14. Harvard Stem Cell Institute, Harvard Medical School, Boston, USA; 15. Depts. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USAShow moreShow less
166
days
Subtype-resolved tumor-intrinsic programs in immune-cold breast cancer: mechanistic interactions, evidence gaps, and translational priorities
Authors
Hung-Yu Lin; Shin-Mae Wang; Pei-Yi ChuShow moreShow less
Affiliations
1. Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan; 2. Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan; 3. Department of Surgery, Show Chwan Memorial Hospital, Changhua, Taiwan; 4. Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan; 5. National Institute of Cancer Research, National Health Research Institutes, Tainan, TaiwanShow moreShow less
224
days
Comparative characterization of OncoPro™ and Wnt-based media reveals distinct phenotypic and pharmacologic states in patient-derived tumor organoids
Authors
Sofie Seghers; Maxim Le Compte; Felicia Rodrigues Fortes; Jana Baroen; Jasper Ott; Geert Roeyen; Vera Hartman; Samir Kumar-Singh; Lenny Coppens; Michiel de Maat; Niels Komen; Sylvie Van Den Broeck; Jody Valk; Wiebren Tjalma; Jeroen M. H. Hendriks; Paul Van Schil; Gilles Van Haesendonck; Sofia L. J. Peeters; Hans Prenen; Christophe DebenShow moreShow less
Affiliations
1. Center for Oncological Research (CORE), , University of Antwerp, Wilrijk, Belgium; 2. Department of Medical Oncology, University Hospital Antwerp (UZA), Edegem, Belgium; 3. Plasma Lab for Applications in Sustainability and Medicine ANTwerp (PLASMANT), University of Antwerp, Wilrijk, Belgium; 4. Environmental Intelligence Unit, Flemish Institute for Technological Research (VITO), Mol, Belgium; 5. Department of Hepatobiliary Transplantation and Endocrine Surgery, University Hospital Antwerp (UZA), Edegem, Belgium; 6. Molecular Pathology Group, Laboratory of Cell Biology & Histology, University of Antwerp, Wilrijk, Belgium; 7. Translational Neurosciences, University of Antwerp, Wilrijk, Belgium; 8. Department of Abdominal, Pediatric and Reconstructive Surgery, Antwerp University Hospital, Edegem, Belgium; 9. Antwerp ReSURG, Anatomy and Research Centre (ASTARC), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; 10. Multidisciplinary Breast Clinic—Unit Gynecological Oncology, University Hospital Antwerp (UZA), Edegem, Belgium; 11. Faculty of Medicine, University of Antwerp, Wilrijk, Belgium; 12. Department of Thoracic and Vascular, Surgery University Hospital Antwerp (UZA), Edegem, Belgium; 13. Department of Otorhinolaryngology, University Hospital Antwerp (UZA), Edegem, BelgiumShow moreShow less
FAQ
How long does Experimental Hematology & Oncology take to review a manuscript?
As of 2026-11-18, CrushSCI has 30 complete review records for Experimental Hematology & Oncology. The fastest paper went from submission to acceptance in 26 days (CAR immunotherapy for cancer: from ex vivo manufacturing to in vivo immune cell engineering, received 2026-10-01, accepted 2026-10-27); the slowest took 282 days. The average is 138.6 days and the median is 131.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
